Difference between revisions of "MR DWI of the ADC, Clinically Feasible Profile"

From QIBA Wiki
Jump to navigation Jump to search
(Created page with "right|frameless|link=https://qibawiki.rsna.org/index.php/File:QIBA_Initials_FIN.JPG ==='''<big>Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf|D...")
 
Line 13: Line 13:
 
The goal of a QIBA Profile is to help achieve a useful level of performance for a given biomarker. The Claim (Section 2) describes the biomarker performance and is derived from the body of scientific literature meeting specific requirements, in particular test-retest studies. The Activities (Section 3) contribute to generating the biomarker. Requirements are placed on the Actors that participate in those activities as necessary to achieve the Claim. Assessment Procedures (Section 4) for evaluating specific requirements are defined as needed to ensure acceptable performance.
 
The goal of a QIBA Profile is to help achieve a useful level of performance for a given biomarker. The Claim (Section 2) describes the biomarker performance and is derived from the body of scientific literature meeting specific requirements, in particular test-retest studies. The Activities (Section 3) contribute to generating the biomarker. Requirements are placed on the Actors that participate in those activities as necessary to achieve the Claim. Assessment Procedures (Section 4) for evaluating specific requirements are defined as needed to ensure acceptable performance.
  
Diffusion-Weighted Imaging (DWI) and the Apparent Diffusion Coefficient (ADC) are being used clinically as qualitative (DWI) and quantitative (ADC) indicators of disease presence, progression or response to treatment [1-29]. Use of ADC as a robust quantitative biomarker with finite confidence intervals places additional requirements on Sites, Acquisition Devices and Protocols, Field Engineers, Scanner Operators (MR Technologists, Radiologists, Physicists and other Scientists), Image Analysts,
+
Diffusion-Weighted Imaging (DWI) and the Apparent Diffusion Coefficient (ADC) are being used clinically as qualitative (DWI) and quantitative (ADC) indicators of disease presence, progression or response to treatment. Use of ADC as a robust quantitative biomarker with finite confidence intervals places additional requirements on Sites, Acquisition Devices and Protocols, Field Engineers, Scanner Operators (MR Technologists, Radiologists, Physicists and other Scientists), Image Analysts, Reconstruction Software and Image Analysis Tools. Additionally, due to the intrinsic dependence of measured ADC values on biophysical tissue properties, both the Profile Claims and the associated scan protocols (Section 3.6.2) are organ-specific. All of these are considered Actors involved in Activities of Acquisition Device Pre-delivery and Installation, Subject Handling, Image Data Acquisition, Reconstruction, Registration, ADC map generation, Quality Assurance (QA), Distribution, Analysis, and Interpretation. The requirements addressed in this Profile are focused on achieving ADC values with minimal systematic bias and measurement variability.
Reconstruction Software and Image Analysis Tools [30-37]. Additionally, due to the intrinsic dependence of measured ADC values on biophysical tissue properties, both the Profile Claims and the associated scan protocols (Section 3.6.2) are organ-specific. All of these are considered Actors involved in Activities of Acquisition Device Pre-delivery and Installation, Subject Handling, Image Data Acquisition, Reconstruction, Registration, ADC map generation, Quality Assurance (QA), Distribution, Analysis, and Interpretation. The requirements addressed in this Profile are focused on achieving ADC values with minimal systematic bias and measurement variability [34, 36, 37].
 
  
 
DISCLAIMER: Technical performance of the MRI system can be assessed using a phantom having known diffusion properties, such as the QIBA DWI phantom. The clinical performance target is to achieve a 95% confidence interval for measurement of ADC with a variable precision depending on the organ being imaged and assuming adequate technical performance requirements are met. While in vivo DWI/ADC measurements have been performed throughout the human body, this Profile focused on four organ systems, namely brain, liver, prostate, and breast as having high clinical utilization of ADC with a sufficient level of statistical evidence to support the Profile Claims derived from the current peer-reviewed literature. In due time, new DWI technologies with proven greater performance levels, as well as more organ systems will be incorporated in future Profiles.
 
DISCLAIMER: Technical performance of the MRI system can be assessed using a phantom having known diffusion properties, such as the QIBA DWI phantom. The clinical performance target is to achieve a 95% confidence interval for measurement of ADC with a variable precision depending on the organ being imaged and assuming adequate technical performance requirements are met. While in vivo DWI/ADC measurements have been performed throughout the human body, this Profile focused on four organ systems, namely brain, liver, prostate, and breast as having high clinical utilization of ADC with a sufficient level of statistical evidence to support the Profile Claims derived from the current peer-reviewed literature. In due time, new DWI technologies with proven greater performance levels, as well as more organ systems will be incorporated in future Profiles.
Line 20: Line 19:
 
This document is intended to help a variety of users: clinicians using this biomarker to aid patient management; imaging staff generating this biomarker; MRI system architects developing related products; purchasers of such products; and investigators designing clinical trials utilizing quantitative diffusion-based imaging endpoints.
 
This document is intended to help a variety of users: clinicians using this biomarker to aid patient management; imaging staff generating this biomarker; MRI system architects developing related products; purchasers of such products; and investigators designing clinical trials utilizing quantitative diffusion-based imaging endpoints.
  
Note that this document only states requirements specific to DWI to achieve the claim, not requirements
+
Note that this document only states requirements specific to DWI to achieve the claim, not requirements that pertain to clinical standard of care. Conforming to this Profile is secondary to proper patient care.
that pertain to clinical standard of care. Conforming to this Profile is secondary to proper patient care.
 

Revision as of 16:43, 24 May 2024

QIBA Initials FIN.JPG

Document (PDF)

Publication Details

Author: QIBA Magnetic Resonance Diffusion-Weighted Imaging (DWI-MR) Biomarker Committee

Version: Stage 3: Clinically Feasible

DOI: <insert>

Publication date: 2022 December 15

Executive Summary

The goal of a QIBA Profile is to help achieve a useful level of performance for a given biomarker. The Claim (Section 2) describes the biomarker performance and is derived from the body of scientific literature meeting specific requirements, in particular test-retest studies. The Activities (Section 3) contribute to generating the biomarker. Requirements are placed on the Actors that participate in those activities as necessary to achieve the Claim. Assessment Procedures (Section 4) for evaluating specific requirements are defined as needed to ensure acceptable performance.

Diffusion-Weighted Imaging (DWI) and the Apparent Diffusion Coefficient (ADC) are being used clinically as qualitative (DWI) and quantitative (ADC) indicators of disease presence, progression or response to treatment. Use of ADC as a robust quantitative biomarker with finite confidence intervals places additional requirements on Sites, Acquisition Devices and Protocols, Field Engineers, Scanner Operators (MR Technologists, Radiologists, Physicists and other Scientists), Image Analysts, Reconstruction Software and Image Analysis Tools. Additionally, due to the intrinsic dependence of measured ADC values on biophysical tissue properties, both the Profile Claims and the associated scan protocols (Section 3.6.2) are organ-specific. All of these are considered Actors involved in Activities of Acquisition Device Pre-delivery and Installation, Subject Handling, Image Data Acquisition, Reconstruction, Registration, ADC map generation, Quality Assurance (QA), Distribution, Analysis, and Interpretation. The requirements addressed in this Profile are focused on achieving ADC values with minimal systematic bias and measurement variability.

DISCLAIMER: Technical performance of the MRI system can be assessed using a phantom having known diffusion properties, such as the QIBA DWI phantom. The clinical performance target is to achieve a 95% confidence interval for measurement of ADC with a variable precision depending on the organ being imaged and assuming adequate technical performance requirements are met. While in vivo DWI/ADC measurements have been performed throughout the human body, this Profile focused on four organ systems, namely brain, liver, prostate, and breast as having high clinical utilization of ADC with a sufficient level of statistical evidence to support the Profile Claims derived from the current peer-reviewed literature. In due time, new DWI technologies with proven greater performance levels, as well as more organ systems will be incorporated in future Profiles.

This document is intended to help a variety of users: clinicians using this biomarker to aid patient management; imaging staff generating this biomarker; MRI system architects developing related products; purchasers of such products; and investigators designing clinical trials utilizing quantitative diffusion-based imaging endpoints.

Note that this document only states requirements specific to DWI to achieve the claim, not requirements that pertain to clinical standard of care. Conforming to this Profile is secondary to proper patient care.